Abbott Laboratories
ABTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Valued at $150.32B, ABT is a large-cap name in its sector. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Market Cap
$150.32B
Beta
0.65
P/E (TTM)
24.17
P/E (Fwd)
14.24
EPS (TTM)
$3.57
EPS (Fwd)
$6.06
ROE
12.3%
ROA
5.6%
Cash
$7.30B
Total Debt
$34.14B
Free CF
$6.34B
52W Change
-35.4%
Annual Financials
Cash vs Debt
The company holds $7.30B in cash, though total debt stands at $34.14B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $6.34B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 12.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $43.65B (2022) to $44.33B (2025).
ABT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing ABT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.